×
Genmab Cash on Hand 2019-2024 | GMAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Genmab cash on hand for the quarter ending June 30, 2024 was
$2.270B
, a
37.55% decline
year-over-year.
Genmab cash on hand for 2023 was
$4.085B
, a
29.23% increase
from 2022.
Genmab cash on hand for 2022 was
$3.161B
, a
2.74% increase
from 2021.
Genmab cash on hand for 2021 was
$3.077B
, a
24.9% increase
from 2020.
View More
Genmab Cash on Hand 2019-2024 | GMAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Genmab cash on hand for 2023 was
$4.085B
, a
29.23% increase
from 2022.
Genmab cash on hand for 2022 was
$3.161B
, a
2.74% increase
from 2021.
Genmab cash on hand for 2021 was
$3.077B
, a
24.9% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$127.1B
Gilead Sciences (GILD)
$114.2B
Bristol Myers Squibb (BMY)
$112.1B
CSL (CSLLY)
$91B
Regeneron Pharmaceuticals (REGN)
$89.7B
GSK (GSK)
$74.4B
Argenex SE (ARGX)
$35.2B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Biogen (BIIB)
$25.4B
BioNTech SE (BNTX)
$25.4B
Illumina (ILMN)
$24.2B
Moderna (MRNA)
$19.9B
BeiGene (BGNE)
$19.7B
Incyte (INCY)
$15.6B
Insmed (INSM)
$13B
Vaxcyte (PCVX)
$13B
BioMarin Pharmaceutical (BMRN)
$12.6B
Sarepta Therapeutics (SRPT)
$12.2B
Bio-Techne Corp (TECH)
$12B
Exelixis (EXEL)
$10.1B
Exact Sciences (EXAS)
$10.1B
QIAGEN (QGEN)
$10B
Revolution Medicines (RVMD)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$8.2B
Ascendis Pharma (ASND)
$7.8B
Halozyme Therapeutics (HALO)
$7.7B